UK markets closed
  • NIKKEI 225

    28,508.55
    -591.83 (-2.03%)
     
  • HANG SENG

    28,621.92
    -513.81 (-1.76%)
     
  • CRUDE OIL

    61.12
    -1.55 (-2.47%)
     
  • GOLD FUTURES

    1,794.40
    +16.00 (+0.90%)
     
  • DOW

    34,084.36
    +263.06 (+0.78%)
     
  • BTC-GBP

    39,837.88
    -640.53 (-1.58%)
     
  • CMC Crypto 200

    1,282.10
    +19.14 (+1.52%)
     
  • ^IXIC

    13,902.13
    +115.87 (+0.84%)
     
  • ^FTAS

    3,935.64
    +15.59 (+0.40%)
     

The global dPCR and qPCR market size is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0%

ReportLinker
·4-min read

The growth of this market is driven majorly by factors such as the rising incidence of target infectious diseases and genetic disorders; technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project.

New York, March 11, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Digital PCR and Real-time PCR Market by Product, Application, End User - Global Forecast to 2025" - https://www.reportlinker.com/p04973888/?utm_source=GNW
On the other hand, high instrument costs—especially that of dPCR—and the technical limitations of PCR are restraining market growth.

By application, the clinical applications segment (of qPCR) is expected to grow at the highest CAGR during the forecast period.
Based on application, the qPCR market is segmented into clinical applications, research applications, and forensic applications.The clinical applications segment is expected to register the highest growth during the forecast period.

The key factors driving the market growth include the growing usage of qPCR in disease diagnosis, rising incidence of infectious & genetic diseases, and growing public emphasis on early & effective disease diagnosis & treatment..
• By end-user, the hospitals and diagnostics centers segment dominated the dPCR market in 2019.

Based on end-user, the dPCR market is segmented into Hospitals and Diagnostic Centers, Research Laboratories and Academic Institutes, Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, and Forensic Laboratories. The Hospitals and Diagnostic Centers segment accounted for the largest share of the dPCR market in 2019, primarily due to the growing demand for early and efficient disease diagnosis and treatment, increasing number of dPCR product launches for diagnostic applications, benefits offered by dPCR in disease diagnosis (as compared to other PCR technologies), and growing public awareness related to the benefits offered by dPCR in disease diagnosis.

Asia Pacific dPCR and qPCR market is expected to witness the highest growth during the forecast period.
The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period, primarily due to the ongoing expansion & modernization of the healthcare infrastructure in emerging Asian countries; increasing number of research projects in China, India, and Japan in the field of genomics and cancer; the rising trend of clinical research being outsourced to Asia-based CROs by leading drug manufacturing companies; and continuous government support for genomics-based research activities in emerging Asia Pacific countries.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–45%, Tier 2–34%, and Tier 3–21%
• By Designation: D-level–14%, C-level–10%, and Others–78%
• By Region: North America–31%, Europe–33%, Asia Pacific–19%, RoW-18%

Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland) are the key players operating in this market. Other prominent players are Abbott Laboratories (US), Agilent Technologies (US), Analytik Jena AG (Switzerland), Becton Dikinson and Company (US), bioMérieux SA (France), Danaher Corporation (US), Eppendorf (Germany), Fluidigm Corporation (US), Merck KGaA (Germany), QIAGEN N.V. (Netherlands), Takara Bio (Japan), Meridian Bioscience (US), Promega Corporation (US), Enzo Life Sciences, Inc. (US), Bioneer (South Korea), ELITech Group (France), and Quidel Corporation (US).

Research Coverage:
The report analyzes the dPCR and qPCR market and aims at estimating the market size and future growth potential. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a more significant share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the dPCR and qPCR market
• Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the dPCR and qPCR market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new systems, growing geographies, and recent developments in the global dPCR and qPCR market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and services of leading players in the dPCR and qPCR market

Read the full report: https://www.reportlinker.com/p04973888/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001